Chiu, C. W., Nozawa, H., & Hanahan, D. (2010). Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis. American Society of Clinical Oncology.
Chicago-стиль цитированияChiu, Christopher W., Hiroaki Nozawa, and Douglas Hanahan. Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis. American Society of Clinical Oncology, 2010.
MLA-цитированиеChiu, Christopher W., Hiroaki Nozawa, and Douglas Hanahan. Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis. American Society of Clinical Oncology, 2010.